All In Biotech

Drug Trial Radar · NCT06981988

A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL

A Study to Explore the Dosage and Efficacy of Linperlisib in Combination With Rituximab and to Validate the Efficacy of Linperlisib in Patients With Relapsed/Refractory Indolent NHL

Last checked: Nov 20, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jun 2025

Primary completion

Aug 2025

Study completion Feb 2027

Sponsor

Sponsor type
Industry
First posted
May 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the reasonable dosage, efficacy and safety of Linperlisib in combination with rituximab in subjects with relapsed/refractory (R/R) indolent non-hodgkin lymphoma(NHL) in adults.

Conditions

  • Relapsed/Refractory Indolent NHL

Interventions

  • Linperlisib ; RituximabDrug

    Linperlisib ; Rituximab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTD (Maximum tolerated dose)of Linperlisib(Stage 1)Time frame: Subjects are evaluated for DLTs during the first 28-day cycle
  2. RP2/3D(Recommended Phase II/III Dose) of Linperlisib (Stage 1)Time frame: The RP2/3D for Phase 2/3 will be selected at the end of Phase 1b, approximately 2 years
  3. Complete response rate (CRR) assessed by Investigator(Stage 2)Time frame: up to 5 years
  4. Progression-free Survival assessed by Investigator (Stage 2)Time frame: up to 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.